News 2015
In This Issue
Early this fall AIDS activists and the medical community were shocked when Turning Pharmaceuticals raised the price of Daraprim (pyrimethamine), a prescription drug used by many PLWHA who have toxoplasmosis, to $750 a tablet, overnight. Here, Tamara Holmes reports on the positive outcome as a result of the public outcry when these communities mobilized.
Price Hike of HIV/AIDS Drug Highlights New Role for Activism
High cost of drugs
There's no denying that many strides have been made in the treatment of HIV/AIDS. But a pharmaceutical company's recent decision to hike the price of a drug used by PLWHA from $13.50 per tablet to $750 overnight has some wondering if such progress could be wiped out at the whim of big business.
Read more: Price Hike of HIV/AIDS Drug Highlights New Role for Activism
California Targets African Americans And Latinos In New Round Of Obamacare
A worker helps an applicant fill out paperwork during a healthcare enrollment fair at the Bay Area Rescue Mission in March 2014 in Richmond, California. This year, the state is doubling-down on trying to get more African Americans and Latinos to sign up for coverage. Use: covered California.
Covered California still faces major challenges in enrolling African-Americans and Latinos as the state's health insurance exchange launches its third open enrollment period Sunday.
Read more: California Targets African Americans And Latinos In New Round Of Obamacare
Hepatitis C in Corrections – A New Resource for Incarcerated People
Hep C in prisons
A disproportionate number of people with hepatitis C (HCV) in the U.S. are or have been inmates in jails and prisons. Correctional settings therefore present significant opportunities to provide hepatitis prevention, testing, care, and treatment interventions. To help incarcerated people understand HCV, the National Hepatitis Corrections Network (NHCN) has introduced a new resource to assist with inmate education efforts.
Read more: Hepatitis C in Corrections – A New Resource for Incarcerated People
Hepatitis C Initiative in Ryan White Clinics—Findings from a Special Program of National Significance
Hepatitis C and HIV co-infection
The Health Resources and Services Administration (HRSA) presented findings and lessons from a four-year demonstration project that supported 29 organizations implementing focused interventions designed to increase access to and completion of hepatitis C (HCV) treatment for people also living with HIV at ID Week, a leading forum for sharing infectious disease research and practice.